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Background: It has been shown previously that novel formulation of 3,3'-diindolylmethane (DIM) substance with
high bioavailability (Infemin) inhibits tumor development due to the tumor growth rate reduction in the xenograft
model of prostate cancer. Prostatic intraepithelial neoplasia (PIN) is considered to be promising as a personalized
and preventive treatment strategy of prostate cancer (PC). We assessed the safety of Infemin in men with PIN and
discussed the interim results.
Materials and methods: A total of 14 patients with PIN were enrolled. They were randomized to 900 mg DIM or
placebo daily for 3 months. Safety was evaluated by adverse events (AEs), laboratory tests and physical
examinations.
Results and conclusion: The trial revealed that Infemin treatment is associated with minimal toxicity and no
serious adverse events when administered orally for 3 months. We noted three adverse events including nausea
and diarrhea in two patients (14%). Combined 95% confidence interval (CI) was 1.8%–42.8%. Therapy was continued
in all cases of adverse events.
Good tolerability of DIM-based formulation allows us to recommend it for further clinical trials among men diagnosed
with PIN for its efficacy and long-term safety parameters.
Keywords: 3,3′-Diindolylmethane, Infemin, Preclinical trials, Bioavailability, Molecularly targeted treatment, Targeted
prevention, Safety, Tolerability, Prostatic intraepithelial neoplasia, Prostate cancer, Personalized medicineOverview
Prostatic intraepithelial neoplasia (PIN) is associated with
cellular proliferations within the lining of acini, prostatic
ducts and ductules. Numerous publications have reported
that PIN is a major risk factor for the development of
prostate cancer (РС) [1,2]. First of all, PIN histologically
has many features in common with РС. Moreover, the in-
creased androgen receptor (AR) activity is present in cases
of intraepithelial neoplasia and PC. AR can function as a
positive regulator of proliferation and stimulate the devel-
opment of neoplasia which indicates a direct role of AR in
promoting PC [3]. Thus, PIN can be predictive for the de-
velopment of РС in the future.* Correspondence: DruhVM@ilmixgroup.ru
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unless otherwise stated.There is substantial evidence that hyperplastic pro-
cesses are associated with exposure to hormones [4].
Androgens stimulate growth, development and func-
tional activity of the normal prostate gland. However,
men as they age pass through a shift in hormones due to
the influence of external and internal factors. The result-
ing imbalance changes the functional activity of the
prostate, the level of androgens and the status of the an-
drogen receptors.
It is considered that testosterone levels play a major role.
The biological activity of testosterone is induced in large
part by its conversion to 5α-dihydrotestosterone (5α-DHT)
by 5α-reductase. Testosterone and 5α-DHT effects are me-
diated through binding to the AR. They stimulate prolifer-
ation of target cells and induce synthesis of IGF-1, TGFβ
and other polypeptide growth factors [5].
Several theories have proposed the role of estrogens
in the prostate physiology. It is considered that theseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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entiation of the prostate. Firstly, they affect cells through
interaction with estrogen receptors (ERs). Classical signal-
ing provides binding of estrogen-ER complex to estrogen
response elements (EREs) in DNA and activates down-
stream estrogen responsive genes. Moreover, hydroxylated
estrogen metabolites 2-hydroxyestrone/16α-hydroxyestrone
(2-OHE1/16α-OHE1) influence the proliferation and in-
duce hyperplasia as a result of the increase in the ratio of
metabolites towards more aggressive 16α-OHE1 [6,7].
Nowadays, there are no standard treatments for PIN
[8]. Thus, drug development based on substances which
target certain pathogenic mechanisms seems promising.
3,3-Diindolylmethane (DIM) is a chemical compound
with anticarcinogenic activity [9]. DIM acts as a pure AR
antagonist that blocks expression of androgen-responsive
genes and inhibits DHT-induced AR translocation and nu-
clear foci formation [10]. Moreover, it has a pronounced
antiestrogenic effect, stimulating the production of 2-
OHE1, thus improving the 2-OHE1/16α-OHE1 ratio [11].
Many studies have emphasized that DIM interferes with
different signaling pathways. According to experimental
data, DIM inhibited growth, angiogenesis and invasion of
prostate cancer cells by regulating Akt, NF-kappaB, VEGF
and the AR signaling pathway [12]. Another important
mechanism of DIM action is the ability to induce apop-
tosis via Bax-Bcl system [13]. Finally, it was demonstrated
that DIM is a selective and potent inhibitor of cancer stem
cells [14].
However, DIM substance has one significant disadvan-
tage. It exhibits low bioavailability in target tissues [15-17].
Infemin is a DIM-based pharmaceutical composition with
enhanced bioavailability of the active substance due to
two components (cod liver oil and polysorbate) that pro-
vide increased solubility of DIM [18]. α-Tocopherol acet-
ate (vitamin E) as a free radical scavenger provides storage
stability of the drug. This novel formulation of DIM
quickly enters the blood and the target organs and reaches
high plasma concentrations. The level of DIM in rat blood
plasma was about fivefold higher, though the 2,000-fold
lower dose was administered, compared to crystalline
DIM forms [19].
It has been shown in the xenograft model of prostate
cancer that Infemin inhibits tumor development due to
the tumor growth rate reduction [20]. Moreover, thera-
peutic effect lasts for 6 days after the cessation of the
Infemin administration. This fact revealed stable positive
changes, caused by multiple targeted action of new for-
mulation of DIM.
We place a special emphasis on investigations dedi-
cated to the integrated diagnosis, treatment and preven-
tion of PC in individual patients (predictive, preventive
and personalized medicine (PPPM)). The ability to re-
verse PIN may delay the development of prostate cancer.Thus, we identify targets due to determination of signs of
the disease at the early stage. Accurate definition of risk
groups allows us to select individuals who are candidates
for prevention strategies. We suggest that the strategy of
treating PIN by addressing key signaling pathways with
DIM-based agents will be effective for PC prevention.
A double-blind, randomized, placebo-controlled, pro-
spective phase Ib clinical trial was performed to determine
the safety and tolerability of a novel DIM-based drug.
Methods
Drug compounds
Infemin consisted of 3,3′-diindolylmethane (150 mg) and
organic components (cod liver oil, polysorbate 80 and α-
tocopherol acetate (vitamin E)) providing high bioavail-
ability and storage stability of the drug [18].
Participants and treatments
Fourteen patients (ages between 18 and 60 years) with
histologically verified PIN, serum PSA < 10 ng/mL and
residual urine volume less than 150 mL were enrolled.
Patients should not have prior therapy of chronic prosta-
titis within 1 month or therapy of prostatic hyperplasia
and prostatic intraepithelial neoplasia within 3 months
before starting study treatment. Exclusion criteria in-
cluded also treatment by any investigational drug pro-
ceeding within 30 days of randomization. Patients who
had a prostate cancer or another tumor, previous surgery
for pelvic organ, acute urinary tract infection, urinary re-
tention, neurogenic bladder dysfunction, stones and di-
verticula, urethral stricture, bladder neck sclerosis and a
flow rate that is less than 5 ml/s were also excluded. Other
exclusion criteria were addiction or chronic alcoholism,
psychiatric disorders and cardiac disease.
Patients underwent clinical screening within 1 month
before baseline. Then, they were randomized to receive
900 mg (three capsules twice a day) DIM or placebo daily.
Subjects were evaluated for 3 months. If serious adverse
events are not present, patients will continue to take Infe-
min and participate in the trial for 12 months.
It was planned that adverse events (AEs) were assessed
through physical examinations at clinic every 3 months
(12-month regimen). Every visit usually lasted 1–5 days.
At visits, clinical laboratory tests such as standard blood
and urine chemistries were performed. Measurement of
vital signs, namely systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), respiratory rate (RR), heart
rate (HR) and electrocardiography were also monitored.
Patients underwent prostate biopsy every 6 months (12-
month regimen).
This study was reviewed and approved by the local
ethic committee of the Peoples' Friendship University of
Russia. Written informed consent was obtained from all
patients.
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Adverse events were tabulated and rated for severity
(mild, moderate and severe). The experimental data were
treated statistically using program package Statistica 8.0
(StatSoft, Inc., Tulsa, OK, USA). Statistical tests were two-
sided with a significance level of 0.05. The 95% confi-
dence interval was computed using the Clopper-Pearson
method. Statistical dependence between the presence of
adverse events and group of study was analyzed by chi-
square exact test (χ2).
Results
We evaluated interim data from the trial of Infemin
safety and tolerability profile. Fourteen patients were ad-
ministered an oral daily dose of Infemin or placebo. All
patients in each group completed the study.
There were three mild adverse events which occurred
in 2 out of 14 men diagnosed with PIN and no serious
adverse events. One patient experienced nausea (AE was
repeated twice). After 3 months, one subject receiving
the test formulation reported diarrhea. Thus, the most
common adverse events were gastrointestinal in nature.
These side effects were mild and transient.
All adverse events in these subjects are listed in
Table 1.
Patients who received the placebo did not report any
side effects. In both groups, there were no reported ser-
ious adverse events or toxicities.
The value for the χ2 after 3 months was 0.157. Thus,
we have found no correlation between AEs and group of
study.
The vast majority of patients (12 out of 14) did not re-
port any drug-related adverse events (86% versus 100%
for placebo). A confidence interval shows the range
within which the true effect is likely to lie. For nausea,
the 95% confidence interval (Clopper-Pearson method)
runs from 0.2% to 33.9%, and for diarrhea, the 95% con-
fidence interval runs from 0.2% to 33.9%. The combined
confidence interval for AEs (95% CI) was 1.8%–42.8%.
Patients ingesting Infemin did not show any clinically
significant changes in various clinical and biochemical
parameters. However, it should be noted that results ofTable 1 Number and percentage of patients reporting





1 (0 day) None 8 (89.0%) 5 (100.0%) 13 (93.0%)
Nausea 1 (11.0%) 0 (0.0%) 1 (7.0%)
2 (90th day) None 7 (78.0%) 5 (100.0%) 12 (86.0%)
Nausea 1 (11.0%) 0 (0.0%) 1 (7.0%)
Diarrhea 1 (11.0%) 0 (0.0%) 1 (7.0%)the study are interim, and there are missing values for a
series of indicators (total protein, albumin, creatinine,
glucose, total bilirubin, ALT, AST). Thus, we were not
able to evaluate change dynamics of these parameters
from screening to the latest visit.
During the study, we have not observed serious ad-
verse events, deaths or adverse events that led to discon-
tinuation of the investigational drug. The intensity of
adverse events in this trial was approved by investigators
as non-significant. All AEs were considered to be prob-
ably unrelated to the experimental drug.
Symptoms caused by drug therapy have been treated in
two out of three cases (one patient with nausea) to elimin-
ate or reduce the AEs. After treatment, the signs and symp-
toms of nausea have disappeared.
In all cases of adverse events, therapy was continued.
Thus, we suggested that the drug Infemin is well tolerated.
Discussion
This phase Ib study of Infemin was performed after pre-
clinical studies suggested tolerability and protective effect
of orally administered DIM formulation which demon-
strated anticancer activity [21].
Safety of DIM was confirmed in several clinical tri-
als. Accordingly to Reed et al., a single dose of BR-DIM
(pharmaceutical composition BioResponse-DIM which
contains pure DIM, microdispersed in spray-dried starch
particles) at 200 mg in healthy subjects, including men
was well tolerated [17].
BR-DIM was also well tolerated by prostate cancer pa-
tients in investigation of Heath et al. [15]. The most com-
mon toxicities reported were diarrhea and hyperglycemia
with no significant changes observed with other laboratory
values. Oral BR-DIM at 2 mg/kg/day for 12 weeks also
had no significant toxicity (two subjects complained of
nausea) [22].
Our findings indicate a good tolerability profile of
Infemin. Based on our clinical experience, side effects of
gastrointestinal complaints (nausea and diarrhea) were
the most commonly reported adverse events that ap-
peared during the treatment. All AEs were considered
unrelated to the investigational drug or probably unre-
lated. However, these side effects were likely related to
the cod liver oil component. In spite of this, cod liver oil
is a necessary component of formulation which provides
high bioavailability of active DIM substance. This phase
Ib trial includes only a small number of patients and was
exploratory. We plan to present final clinical trial data in
the first calendar quarter of 2015.
As men examined in this study are at high risk for pros-
tate cancer, our findings are of particular interest. Infemin
treatment may be considered as a novel approach for pre-
ventive therapy of PC in personalized medicine. We con-
firmed good tolerability of novel DIM-based formulation
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ment of PIN requires long-term therapy (for 1 year).
Thus, Infemin will be investigated during further clinical
trials among men diagnosed with PIN for its efficacy as
well as long-term safety parameters.
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